Class 2 Medicines Recall: Accord-UK Ltd, Lercanidipine Hydrochloride 10mg Film-Coated Tablets, EL(26)A/45
Read and act on the official notice on GOV.UK
The defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious.
What all four recall classes mean
| Class | Action | The MHRA's definition |
|---|---|---|
| Class 1 | Immediate action | The defect presents a risk of death or disability. |
| Class 2 this recall | Action within 48 hours | The defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious. |
| Class 3 | Action within 5 days | The defect is unlikely to cause harm to the patient. |
| Class 4 | Caution in use | Usually minor defects in packaging or other printed materials. |
A Class 1 recall usually comes with a National Patient Safety Alert. Source: MHRA, safety communications.
In plain English, for the pharmacy team
Why is this relevant to community pharmacy
Lercanidipine is a medicine used for high blood pressure. This Class 2 medicines recall is because one batch may have a wrong-strength blister strip inside some packs. It affects pharmacists and dispensers who may still have stock, and anyone supplying this medicine to patients.
What to tell patients
Use your professional judgement for each patient.
- If your pack contains blister strips labelled as Lercanidipine Hydrochloride 10 mg Tablets, you do not need to do anything and may carry on taking them.
- If your pack contains a blister strip labelled as Lercanidipine Hydrochloride 20 mg Tablets, do not take it and contact your pharmacy.
- If you think you have taken the 20 mg tablets and have side effects such as dizziness, headache, flushing or palpitations, seek immediate medical advice.
- If you are unsure or have questions, ask your pharmacy or other healthcare professional involved in your care.
- Report suspected side effects through the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card scheme.
What needs to be done
- Stop supplying the affected batch straight away.
- Quarantine all remaining stock of the batch listed in the notice.
- Return the stock to your supplier using your supplier’s approved process.
- Pharmacists: if a patient brings in a pack and it contains the wrong-strength blister strip, use your professional judgement to supply the correct medicine.
- Be aware this recall is at pharmacy and wholesaler level and is not directed at patient level, as the risk of harm to patients is regarded as low, and the 20 mg strength is within the authorised dose range for routine use.
- Read and act on the official GOV.UK notice.
Pharmshark summary, checked and approved by Chris Dotchin on 1 Nov 2026. It is not the official notice: always read and act on the GOV.UK notice.
How this summary was written
An AI tool drafted it from the MHRA's own notice and nothing else. A second check compared every line with the notice. Pharmshark's clinical lead then read it against the notice, edited it where needed and approved it. If the MHRA changes the notice, this summary is taken down until it has been checked again.
The MHRA's summary
Accord-UK Ltd is recalling one batch of Lercanidipine Hydrochloride 10mg Tablets due to a packaging mix-up involving the incorrect strength.
Affected batches
As listed by the MHRA, exactly as published. Always check against the GOV.UK notice before acting.
| Batch number | Expiry | Pack size | First distributed |
|---|---|---|---|
| Lercanidipine Hydrochloride 10mg Film-Coated Tablets | |||
| M2510877 | 11/2028 | 28 | 24/06/2026 |
MHRA's audience tags: Cardiology, Dispensing GP practices, Pharmacy